SNX3

Across TCGA pan-cancer cohorts, SNX3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SNX3 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SNX3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SNX3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where SNX3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	IV	0.199	0.752	.024	3	view →
HNSC	DFS	Median	III,IV	0.932	1.000	.023	3	view →
LSCC	OS	Quartile	All	0.680	0.872	.028	2	view →
LUAD	DFS	Quartile	All	0.746	0.363	.039	2	view →
CCRCC	OS	Tertile	II,III,IV	0.962	0.668	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SNX3–PDAC (DFS)

Open the PDAC breakdown →